(Q33417117)

English

Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

chronic lymphocytic leukemia and small lymphocytic lymphoma

0 references

1 reference

based on heuristic

inferred from title

author name string

Luciano J Costa

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Suzanne R Fanning

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joe Stephenson

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lawrence B Afrin

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Emily Kistner-Griffin

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tricia A Bentz

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Robert K Stuart

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

645-649

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.935369

21 January 2018

Identifiers

10.3109/10428194.2014.935369

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33417117&oldid=1603029707"